Intellia Therapeutics

Jennifer Doudna, a woman whose work has triggered the explosion in innovation in the field of synthetic biology and has given researchers around the world a way to program and reprogram the living wor

The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing te

CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauv

Gene editing is going to fundamentally change our lives and how we traditionally think about health throughout the first half of the 21st century. The question isn’t "When will gene editing become a